Zanidatamab with Standard-of-Care for HER2-Positive Biliary Tract Cancer
This study is looking at a new treatment approach for advanced HER2-positive biliary tract cancer, which includes gallbladder cancer and cholangiocarcinoma. Researchers are testing the safety and effectiveness of Zanidatamab, given with standard chemotherapy (Cisplatin and Gemcitabine), and potentially with an additional drug like Durvalumab or Pembrolizumab. This combination aims to be a first-line treatment. To join, you must have HER2-positive biliary tract cancer that is advanced or has spread and cannot be removed by surgery. The main goal is to see how long people live without their cancer getting worse (Progression Free Survival). The study plans to enroll 286 participants, but its current status is unclear.
- Study design
- This study is an interventional trial planning to enroll 286 participants. It is evaluating different drug combinations for advanced HER2-positive biliary tract cancer.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- The study will measure Progression Free Survival for up to 52 months.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer
At a glance
Conditions
Where it's being run
185 sites across 99 statesWho to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Progression Free Survival (PFS) in participants with Immunohistochemistry (IHC) 3+ tumorsUp to 52 months
PFS is defined as the time from the date of randomization to the date of documented disease progression, or death from any cause.